MASH – Medxy AI

ION224: A Promising Antisense Oligonucleotide Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

By MedXY 08/27/2025

The phase 2 ION224-CS2 trial demonstrates that ION224, a DGAT2 antisense oligonucleotide, safely improves liver histology in MASH patients independent of weight loss, offering a potential new therapeutic approach.

Clinical Updates Wellness & Lifestyle

HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies

By MedXY 08/24/2025

HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.

Clinical Updates Wellness & Lifestyle

Dapagliflozin Shows Promising Benefits for Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Landmark Multicentre Trial

By MedXY 08/13/2025

Dapagliflozin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis outcomes without increasing adverse events, according to a rigorous 48-week randomized trial.

Clinical Updates Wellness & Lifestyle

Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis: Promising Phase 2a Results

By MedXY 08/02/2025

Efimosfermin alfa, a long-acting FGF21 analogue, demonstrated a favorable safety profile and significant reductions in hepatic fat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a phase 2a randomized controlled trial.

Clinical Updates Medical News

Efruxifermin for Compensated Liver Cirrhosis in MASH: Phase 2b Results and Clinical Implications

By MedXY 08/01/2025

A phase 2b trial found that efruxifermin did not significantly improve fibrosis at 36 weeks in patients with compensated cirrhosis due to MASH, though longer-term benefit was suggested at 96 weeks.